Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biophytis ( (BPTSY) ) has shared an update.
On February 27, 2026, Biophytis announced amendments to its bond financing agreement with Hexagon Capital Fund, doubling the maximum nominal amount from €1 million to €2 million and extending the subscription period from July 31, 2026 to December 31, 2027. The move increases the company’s drawing capacity to €1.35 million as of February 26, 2026, extends its cash runway by about four months, and is framed by management as a vote of confidence in its strategy and late-stage clinical programs in obesity and sarcopenia.
Under the revised terms, each bond bears 12% interest and is redeemable in cash on a bi-monthly schedule over 24 months, while in a default scenario the debt could be repaid in shares at a fixed premium price, implying potential but limited dilution for existing shareholders. Backing from Hexagon Capital Fund, which specializes in financing European SMEs via bonds and equities, underscores continued institutional support for Biophytis at a capital-intensive stage of development, giving the biotech added financial flexibility to advance its pipeline in high unmet-need indications.
The most recent analyst rating on (BPTSY) stock is a Hold with a $0.65 price target. To see the full list of analyst forecasts on Biophytis stock, see the BPTSY Stock Forecast page.
Spark’s Take on BPTSY Stock
According to Spark, TipRanks’ AI Analyst, BPTSY is a Neutral.
The score is primarily held down by weak financial performance (no revenue, ongoing cash burn, and negative equity), reinforced by bearish technicals with the stock trading below major moving averages. Valuation is also constrained by negative earnings and no dividend support, with only a minor offset from oversold momentum readings.
To see Spark’s full report on BPTSY stock, click here.
More about Biophytis
Biophytis SA is a clinical-stage biotechnology company developing drug candidates for age-related diseases, with a lead molecule BIO101 targeting muscular conditions such as sarcopenia and Duchenne muscular dystrophy, respiratory diseases including COVID-19, and metabolic disorders like obesity. Headquartered in Paris with subsidiaries in Cambridge, Massachusetts and Brazil, the company is listed on Euronext Growth Paris and its ADS trade on the U.S. OTC market.
Average Trading Volume: 754
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.56M
See more insights into BPTSY stock on TipRanks’ Stock Analysis page.